CN| EN

Home > News  > Company News

The Chinese “National Reference Materials for BRCA Gene Mutation Testing” has been released which is developed by Annoroad’s participation

2017-11-07

Recently, National Institutes for Food and Drug Control (NIFDC) has authoritatively released the Notice on Publishing the Fourth National Standard and Reference Materials Dictionary for In-vitro Diagnostic Reagents for Registration and Testing, where the “National Reference Materials for BRCA Gene Mutation Testing” developed by Annoroad as a cooperative unit has been included in the national standard and reference materials dictionary of in-vitro diagnostic reagents successfully.


image.png


The matter that the national reference materials for BRCA gene mutation testing is included in the national standard and reference materials dictionary of in-vitro diagnostic reagents is an exciting news for breast cancer patients, breast cancer high risk groups, breast cancer diagnosis and treatment researchers and even the entire gene sequencing industry. The national reference materials for BRCA gene mutation testing can not only provide a basis for the accuracy of BRCA gene testing results but also regulate the declaration of future BRCA gene testing kits. 


image.png


The reason why Annoroad obtains the recognition and trust of NIFDC in BRCA gene testing, it roots in Annoroad’s continuous explorations and practices in establishing Gene Mutation Database and National Testing Standard for breast cancer high risk groups in China.

As early as 2015, the topic of “Genetic Screening for Breast Cancer High Risk Groups in China” was officially launched, which was sponsored by China Health Promotion Foundation with the Southwest Hospital, Third Military Medical University as the organizer and Annoroad as the unique testing party, together with 40 large class A tertiary hospitals in the country. Through more than one years of unremitting efforts, Annoroad has collected and completed the testing of more than a thousand topic samples and carried out multi-dimensional analyses and arrangements to the data, and the result of this topic was released in the 9th National Breast Cancer Forum in Chongqing & Sino-European Annual Conference on Breast Cancer in 2016 by Professor Jiang Jun, the leader of topic group and the director of breast surgery of Southwest Hospital, Third Military Medical University.

The abstract of this topic research was authoritatively included in the 15th St. Gallen International Breast Cancer Conference, which reflects the attention and recognition of international diagnosis and treatment field of breast cancer to Chinese breast cancer experts and their research results and reflects the preciseness and innovation of design and result of this topic research. Annoroad, as the unique technical provider of this topic, has highlighted its profound technical strength in genetic testing. 



As one of the first Genetic Testing Technology and Application Demonstration Center of National Development and Reform Commission and the Precision Medicine and Gene Engineering Beijing Engineering Lab, Annoroad has been engaged in the research, development and innovation of precision medicine technology and will continue to contribute to the technical progress of the cancer genomics in China. 


Copyright2012 Annoroad.com

All rights reserved Annoroad Gene Technology 京ICP备12029022号-1